Hepatic impairment has the potential to alter a drug’s pharmacokinetic (PK) and pharmacodynamic (PD) profile.

A single dose of apixaban was well tolerated and the PK/PD profile of apixaban was comparable between healthy subjects and subjects with mild and moderate hepatic impairment.

These PK and PD data may support administration of apixaban without dose adjustment in patients with mild or moderate hepatic impairment; however, the results should be interpreted cautiously, especially in the presence of more severe hepatic impairment or other risk factors for bleeding.